AVITA Medical (AVH) has received US Food and Drug Administration (FDA) approval for its premarket approval application for its RECELL Autogenous Cell Harvesting Device. The RECELL system is a device designed for the treatment of acute thermal burns. It enables healthcare professional to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin. The company has updated the device in order to provide clinicians with a more efficient user experience and simplified workflow.